Non-Melanoma Skin Cancer Treatment Market Key Players : Almirall S.A., Boehringer Ingelheim GmbH

In a new report titled ‘Non-Melanoma Skin Cancer Treatment Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025,’ Persistence Market Research analyzes the global non-melanoma skin cancer treatment market over an eight year forecast period 2017 – 2025 and throws light on the various factors impacting revenue growth of the market over the said period. The report highlights the market forecasts for the different segments and presents deeper insights for informed decision making.

Region – High Prevalence of Non-Melanoma Skin Cancer in North America

North America is estimated to hold a market share of roughly 55% in the global non-melanoma skin cancer treatment market in 2017 and is anticipated to have the highest attractiveness index of 3.0 during the forecast period. Non-melanoma skin cancer is more prevalent in senior citizens and the Population Reference Bureau estimates that Americans over the age of 65 will double to almost 100 million by 2060.

Request For Report Sample@ https://www.persistencemarketresearch.com/samples/3648

Treatment Type – Radiation Therapy Larger than Chemotherapy and Photodynamic Therapy

Radiation therapy is larger than chemotherapy and photodynamic therapy combined, making it imperative for key stakeholders in the non-melanoma skin cancer treatment market to focus on this treatment type. Radiation therapy is poised to be worth more than US$ 4.7 Bn by end 2025. Within radiation therapy, companies may wish to target superficial radiation therapy.

Indication – Basal Cell Carcinoma Dominates the Non-Melanoma Skin Cancer Treatment Market

Even though squamous cell carcinoma is predicted to record a higher CAGR of 6.4% from 2017-2025, it is unlikely to outpace basal cell carcinoma anytime soon as the latter is likely to value at approx. thrice the size of the former by end 2025. The attractiveness index of basal cell carcinoma is 1.5, considerably larger than the 0.5 of squamous cell carcinoma during the same period.

End User – Hospitals Popular Channel in the Non-Melanoma Skin Cancer Treatment Market

The treatment modalities for non-melanoma skin cancer usually require expensive radiation therapy. Therefore, hospitals are preferred over ambulatory surgical centers and specialty clinics in the non-melanoma skin cancer treatment market. The hospital segment is expected to reach a value of US$ 2 Bn in 2017 itself.

Request For Report Table of Content (TOC): https://www.persistencemarketresearch.com/methodology/3648

Competition Dashboard in the Non-Melanoma Skin Cancer Treatment Market

Persistence Market Research has profiled some of the largest companies actively involved in the non-melanoma skin cancer treatment market. These include Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Elekta AB, F. Hoffmann-La Roche Ltd., Merck & Co., Novartis AG, Mylan NV, Sun Pharmaceutical Industries, Varian Medical Systems, and Sensus Healthcare.

ABOUT US:
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

CONTACT:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.